04:16 PM EST, 11/12/2025 (MT Newswires) -- Ascendis Pharma ( ASND ) reported a Q3 loss late Wednesday of 1 euro ($1.16) per diluted share, narrowing from the loss of 1.72 euros a year earlier.

Analysts polled by FactSet expected a loss of 0.24 euros.

Revenue in the three months ended Sept. 30 rose to 213.6 million euros from 57.8 million euros a year earlier.

Analysts surveyed by FactSet expected 213.2 million euros.